Advertisement
Advertisement
Alector’s Latozinemab Study: A Promising Continuation for Neurodegenerative Disease Treatment
PremiumCompany AnnouncementsAlector’s Latozinemab Study: A Promising Continuation for Neurodegenerative Disease Treatment
17d ago
Alector’s Strategic Potential in Biotechnology: Buy Rating Justified Despite Price Target Reduction
Premium
Ratings
Alector’s Strategic Potential in Biotechnology: Buy Rating Justified Despite Price Target Reduction
22d ago
Alector price target lowered to $5 from $10 at H.C. Wainwright
Premium
The Fly
Alector price target lowered to $5 from $10 at H.C. Wainwright
22d ago
Alector downgraded to Hold from Buy at TD Cowen
PremiumThe FlyAlector downgraded to Hold from Buy at TD Cowen
23d ago
Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings
Premium
The Fly
Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings
23d ago
Alector discontinues extension portion of INFRONT-3 trial
Premium
The Fly
Alector discontinues extension portion of INFRONT-3 trial
23d ago
Alector’s Strategic Positioning and Innovative Approach in Neuroscience Earns Buy Rating
PremiumRatingsAlector’s Strategic Positioning and Innovative Approach in Neuroscience Earns Buy Rating
2M ago
Alector’s Diversified Pipeline and Growth Potential: Analyst Recommends Buy Rating
Premium
Ratings
Alector’s Diversified Pipeline and Growth Potential: Analyst Recommends Buy Rating
2M ago
Alector’s Strategic Collaborations and Promising Developments Drive Buy Rating
Premium
Ratings
Alector’s Strategic Collaborations and Promising Developments Drive Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100